<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2952">
  <stage>Registered</stage>
  <submitdate>11/10/2010</submitdate>
  <approvaldate>11/10/2010</approvaldate>
  <nctid>NCT01222962</nctid>
  <trial_identification>
    <studytitle>Food Interaction Study on the Pharmacokinetics of Eurartesim (DHA and PQP)in Healthy Male Adult Volunteers</studytitle>
    <scientifictitle>Study of the Effect of Food on the Pharmacokinetics of DHA and PQP After Single Oral Administration of Eurartesim in Healthy Male Adult Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ST3073/ST3074-DM09-008</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Malaria, Falciparum</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Eurartesim

Experimental: fed treatment - 18 healthy volunteers administered with a single dose of Eurartesim

Experimental: Fasted Treatment - 18 healthy volunteers treated with a single dose of Eurartesim


Treatment: drugs: Eurartesim
Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 4 Tablets a Day for body weight above 75 kg.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>tmax, Cmax, AUC0-last, AUC0-24 [PQ], and AUC0-inf, ?z, t1/2, Cl/F, Vz/F [DHA]. - Blood samples for determination of plasma DHA were collected at the following times: At pre-dose Day 0 and then at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, and 12 hours post-dose.
Blood samples for determination of plasma PQ were collected at the following times: At pre-dose Day 0 and then at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose; on Day 1, 2, 3, 4, 5 and 7.</outcome>
      <timepoint>from the day of study drug administration, till Day 7 follow-up</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Treatment Emergent Adverse Events - Number of TEAEs and number of Subjects experiencing Adverse Events during all the study period</outcome>
      <timepoint>Day 0 and till Day 30 follow-up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hematology and blood chemistry changes respect to baseline values - Abnormalities in hematology (Haemoglobin, Hematocrit,RBC count, White cell count and differential count, Platelets) and clinical chemistry (Protein, Sodium, Potassium, Chloride ,Total Bilirubin, Conjugated Bilirubin, Alanine Aminotransferase, Aspartate Aminotransferase, Total Cholesterol, Glucose, Bicarbonate, Urea, Urate, Lactate Dehydrogenase, Albumin, Globulins, Triglycerides, Creatinine, Alkaline Phosphatase, Gamma glutamyltransferase, Total Calcium, Phosphate, C-reactive protein) will be recorded the day of the last study drug intake and after 30 days from the start of the drug treatment</outcome>
      <timepoint>Day 0, day 2, day 30</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>QTc interval prolongation - ECG recordings will be obtained at baseline, after the last drug intake and 30 days follow-up to investigate changes in ECG parameters, and specifically QTc interval changes respect to baseline</outcome>
      <timepoint>Day 0, day 2, day 30</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Caucasian healthy males aged between 18 and 50 years(inclusive).

          -  Body Mass Index (BMI) between 19.0 kg/m2 and 27.0 kg/m2 inclusive, with a minimum body
             weight of 75 kg.

          -  Agreed to use two approved methods of contraception from Screening and until 90 days
             after administration of the study drug

          -  Had given written informed consent to participate in this study in accordance with
             local regulations.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Had received or was anticipated to receive a prescription medication within 14 days
             prior to the start of dosing or an over-the-counter medicine 48 hours prior to the
             start of dosing.

          -  Abnormal laboratory test results deemed clinically significant by the Medical Officer.

          -  Positive urine drug test (e.g. opiates and cannabinoids) or alcohol breath test.

          -  History of significant drug allergies or significant allergic reaction.

          -  Receipt of blood or blood products, or loss or donation of 450 mL or more of blood
             within 90 days before the first dose administration.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>37</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>CMAX, a division of IDT Australia Limited - Adelaide</hospital>
    <postcode>SA 5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>sigma-tau i.f.r. S.p.A.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>CPR Pharma Services Pty Ltd, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study was designed to assess the effect of food on the extent and rate of absorption of
      Dihydroartemisinin (DHA) and Piperaquine Phosphate (PQP) administered as a fixed dose
      combination (Eurartesim).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01222962</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>